We'll start on the last question. It was directed to me.
My point was that the CDR was focused on cost and not on the actual value of the medications, that it's an exercise in cost containment, and for that reason I don't think it serves patients very well. So I'm providing an alternative approach to the CDR, something that would essentially say that if we do this, we don't need the CDR; we don't need central planning control over the kinds of drugs patients get. We can simply allow that decision to remain in the hands of patients and their physicians by redesigning our drug plans.
B.C., by the way, has a deductible for eligibility for drug coverage, and other plans have co-payments. Private sector plans have co-payments. The international jurisdictions of the OECD have co-payments and deductibles and user fees as part of their plans as well. So this is not radical stuff; it's being done all over the world quite successfully.
The point is that by introducing those things you create the financial capacity to pay for new expensive technologies and you allow people to pay for affordable things, which is what insurance is supposed to do. Insurance is supposed to cover those things that are impossible for individuals to afford on their own. So I'm simply suggesting that it would free up the capacity to pay for the things through the public programs we're talking about here today.